Complementing our findings, previous studies have reported perturbations in PIK3CA, an oncogene part of the ERBB2/PI3K/AKT/mTOR pathway with a battery of druggable targets, present in over 50% of cervical tumor and cervical cancer cell lines [3]. The gene discussed is ERBB2; the disease is uterine cervix neoplasm.